Ipca Laboratories has acquired Onyx Scientific, a chemistry solutions provider, which will continue to operate out of its Sunderland, UK facility as Onyx Scientific. Onyx Scientific’s chemistry capabilities for medicinal, preclinical and Phase I/II programs adds to Ipca’s capabilities supporting Phase II to commercial scale programs.

Tony Flinn, chief executive officer at Onyx, said, “The combined entity of Onyx Scientific and the Covenance division of Ipca will offer customers comprehensive solutions. Early development projects can be delivered from our UK site with speed and flexibility while optimization, scale-up, and competitive manufacturing for late phase projects can be carried out from Ipca’s locations in India.”

Pranay Godha, Ipca’s executive director, added, “We are very excited about this venture as we can now offer integrated services across the pharmaceutical life cycle with optimal speed, quality and cost offering.”